Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Persistent viral infection with viral reservoirs and detection of circulating spike protein
after the initial acute illness is one potential pathogenic mechanism for Long COVID. This
mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial
will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult
population.